Today’s pharmaceutical companies are facing enormous challenges most prominent of which is the rapidly escalating cost of discovering and developing novel therapeutics coupled with declining R&D productivity.  It is becoming increasingly common for large companies to source innovation outside their own R&D organisations.  However, small biotechnology/pharmaceutical companies, which in the past have provided many innovative programmes, are now finding it increasingly difficult to source investment in their ground-breaking science owing to the current harsh economic climate.

It is also difficult for investors and entrepreneurs to find opportunities that combine innovative concepts with a management team providing a proven track record in the delivery of novel therapeutics.  Scientists generating such ideas seldom have experience in managing drug discovery and development programmes, or in the running of commercial companies, where the main focus is on adding value. While it is essential for all pharmaceutical companies to carry out their programmes in the most efficient way possible, it can be difficult for innovators to identify such efficiencies because lack of appropriate drug-hunting experience can often lead to failure to recognize key value adding steps.

GrantaBio’s business model is to make available to the wider pharmaceutical and biotech communities the extensive and proven experience of its founding partners, thus assisting clients to add real value at key stages of the drug discovery and development process, in the most economical way possible.